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Abstract
Background: The scarcity of grafts available necessitates a system that considers expected posttransplant survival, in
addition to pretransplant mortality as estimated by the MELD. So far, however, conventional linear techniques have failed to
achieve sufficient accuracy in posttransplant outcome prediction. In this study, we aim to develop a pretransplant predictive
model for liver recipients’ survival with benign end-stage liver diseases (BESLD) by a nonlinear method based on
pretransplant characteristics, and compare its performance with a BESLD-specific prognostic model (MELD) and a general-
illness severity model (the sequential organ failure assessment score, or SOFA score).
Methodology/Principal Findings: With retrospectively collected data on 360 recipients receiving deceased-donor
transplantation for BESLD between February 1999 and August 2009 in the west China hospital of Sichuan university, we
developed a multi-layer perceptron (MLP) network to predict one-year and two-year survival probability after
transplantation. The performances of the MLP, SOFA, and MELD were assessed by measuring both calibration ability and
discriminative power, with Hosmer-Lemeshow test and receiver operating characteristic analysis, respectively. By the
forward stepwise selection, donor age and BMI; serum concentration of HB, Crea, ALB, TB, ALT, INR, Na
+; presence of
pretransplant diabetes; dialysis prior to transplantation, and microbiologically proven sepsis were identified to be the
optimal input features. The MLP, employing 18 input neurons and 12 hidden neurons, yielded high predictive accuracy, with
c-statistic of 0.91 (P,0.001) in one-year and 0.88 (P,0.001) in two-year prediction. The performances of SOFA and MELD
were fairly poor in prognostic assessment, with c-statistics of 0.70 and 0.66, respectively, in one-year prediction, and 0.67
and 0.65 in two-year prediction.
Conclusions/Significance: The posttransplant prognosis is a multidimensional nonlinear problem, and the MLP can achieve
significantly high accuracy than SOFA and MELD scores in posttransplant survival prediction. The pattern recognition
methodologies like MLP hold promise for solving posttransplant outcome prediction.
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Introduction
Orthotopic Liver transplantation (OLT) has become an
established treatment approach for patients with benign end-stage
liver diseases (BESLD, i.e. non-neoplastic diseases), but the
growing scarcity of grafts compared to numbers of waiting
patients, coupled with the high cost of this procedure, make it
imperative to make difficult decisions about how to distribute such
scarce organs [1–3], and highlight the need to identify patients
likely to have relatively good outcomes after transplantation [4–6].
This need is particularly acute in the Asia-Pacific region, where the
carrier rate of hepatitis B virus (HBV) is estimated at 20%–30%
[7,8] and large numbers of BESLD patients with HBV-related
cirrhosis and severe hepatitis B need OLT. Under such
circumstances, the ideal allocation system would allocate livers
to candidates who are most likely to die without a transplant, but
who also have a high probability of survival after OLT. The
balanced application of a model for liver transplant outcome
estimation, in concert with a model for end-stage liver disease
(MELD) estimating disease severity, would improve transplant
outcomes and maximize patients’ benefit from OLT [9].
In order to incorporate likely posttransplant prognosis into
decisions about grafts allocation, and to facilitate informed
decision-making by potential transplant recipients and their
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31256relatives [10–12], it is necessary to accurately assess the likelihood
of posttransplant survival based on information that is available
before transplantation.
Although there have been some attempts to develop a model
that meets this requirement, most lacked sufficient discriminating
accuracy or simply stratified the prognostic risk [4,6,9,11–14].
One major reason for this is inappropriate choice of modeling
method [13]. Survival prognosis is a complex nonlinear relation-
ship affected by many interactive factors, especially for a
complicated organ transplantation procedure; however, most
current models were developed by linear methods, such as
multiple regression.
Artificial neural network (ANN) is a computer-based nonlinear
data mining mode that can recognize relationships between a
series of independent variables and the corresponding dependent
variable. It is more successful than traditional linear methods when
the prognostic effect of a variable is influenced by other variables
in a complex multidimensional nonlinear function, or when the
importance of a given prognostic variable is expressed as a
complex unknown function of the value of the variable [15,16].
Thus, ANN is particularly suited to modeling complex multidi-
mensional patterns [17,18], and has had remarkable success in
many medical problems that are too complicated for linear models
[15,19,20]. To date, there have been a few attempts to use ANN
for outcome prediction after organ transplantation [17,21,22], but
no reliable ANN model had been developed specifically for
BESLD recipients.
We investigated the feasibility of using multi-layer perceptron
(MLP), arguably one of the most efficient ANN for prognostic
research [22,23], to develop a prognostic model to predict
individualized survival probability after deceased donor OLT in
recipients with BESLD, employing typically available, objective
preoperative characteristics. Furthermore, we evaluated and
compared the predictive accuracy of this MLP network with a
BESLD-specific prognostic model (MELD) and a general-illness
severity prognostic model (the sequential organ failure assessment
score, or SOFA score).
Methods
Data source
Between February 1999 and August 2009, 386 adults with
BESLD received deceased-donor (either no heartbeat or brain
dead) liver transplants at the 4300-bed West China Hospital of
Sichuan University. We excluded 15 recipients with combined
organ transplants or partial organs and 11 recipients with
incomplete follow-up records. The remaining 360 transplants
were involved in this study and followed up by August 31, 2010.
Maintenance immunosuppression initially consisted of a triple-
drug regimen that included either tacrolimus or cyclosporine,
mycophenolate, and prednisone; and that recipients were
eventually weaned to dual or single agent.
We extracted demographic characteristics of donors and
recipients, pretransplant clinical records (Tables 1 and Table
S1), and recipients’ follow-up information form the electronic
database of the liver transplantation center at West China
Hospital. Surgical and some donor factors were not included in
the model development, since they could not have been known
when recipients decided whether to undergo OLT and were
ranked on the waiting list. All included data were taken from the
most recent examinations prior to transplantation, since they
reflected the current medical condition of the candidate at time of
transplantation.
All organ donations recorded in the electronic database were
contributed voluntarily, and no grafts were obtained from
executed prisoners or other institutionalized persons. All of the
donors or their families had provided written, valid informed
consent for donation before the organs were procured. Each liver
donation and transplantation in our center was approved by the
Medical Ethics Committee of West China Hospital, Sichuan
University, and the study protocol was carried out in accordance
with the Declaration of Helsinki.
Dataset division
A data-splitting approach was used in this study. The recipients
were randomly divided into a modeling set (80% of the total
sample, 290 recipients) used to construct the MLP network, and a
validation set (20% of the total sample, 70 recipients) used to assess
the models’ predictive accuracy; the validation samples would not
be involved in the model development. The modeling set was
randomly re-divided into a general training set (80% of the
modeling set, 232 recipients) and a cross validation set (20% of the
modeling set, 58 recipients) to perform the internal cross validation
in MLP training.
Statistical analysis
Continuous variables were reported as mean 6 standard
deviation and compared using Student’s t test; categorical
variables were reported as numbers and percentages, modeled as
dummy variables, and compared using the chi-square test. A value
of P,0.05 was considered significant in all the analyses. All
analyses, except the MLP development, were carried out using
SAS 8.0.
MELD and SOFA scores calculation
The BESLD-specific illness severity was evaluated by the
MELD and MELD-Na
+ scores, which were calculated according
to the following formulas: MELD=3.786loge TB (mg/
dl)+11.206loge INR+9.576loge Crea (mg/dl)+6.4 [24], MELD-
Na
+=MELD - Na
+2(0.0256MELD6(1402Na
+))+140 [25].
The general illness severity was assessed by the SOFA score,
which is composed of scores from six organ systems (respiratory,
coagulation, liver, cardiovascular, renal, and neurological) graded
from 0 to 4 points according to normal function or the degree of
dysfunction [26] (Table 2).
The MLP network development
An MLP consists of a densely interconnected set of units. In this
study, we developed a three-layer network which not only can
approximate any reasonable function to any degree of required
precision as long as the hidden layer is large enough, but also has
an advantage in computing speed compared to multiple hidden
layer networks [27]. The concept of a neuron is a high-level
abstraction that encompasses both certain values and a set of
operations that are performed on those values, and neurons are
tied together with weighted connections. The MLP was developed
using STATISTICA 8.0.
Determination of input neurons. We performed the
forwards stepwise selection algorithm to screen and identify the
input feature variables from the candidate variables (Table 1 and
Table S1), in which quantitative variables were assigned one-to-
one to the neurons and each sub-category of every categorical
variable was defined as an input neuron. All input quantitative
variables were scaled linearly between 0 and 1.0 using the
following transformation formula, where min{xij} and max{xij}
were the minimum and maximum values of the variable. The
A Predictive Model for Liver Transplants
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yij~
xij{ min
0ƒiƒn
xij

max
0ƒiƒn
xij

{ min
0ƒiƒn
xij

Determination of output neuron. The probability of
survival at posttransplant one year and two years was entered as
continuous output on the interval 0–1, in which 0 represents death
and 1 represents survival, so the MLP output values represent the
probability of posttransplant recipient survival. Survival was
chosen as the outcome endpoint because it is the most reliable
and unbiased variable in the prognostic research [28].
Determination of hidden neurons and network transfer
function. The hidden neurons calculate the weighted sum of
inputs from the input neurons and produce the output result
through an activation algorithm (i.e. transfer function). The
weights are adjusted based on the training data in order to
minimize the error estimate function [29]. Therefore, the
approximate number of hidden neurons and the corresponding
transfer function are closely related to the predictive accuracy of
the network. In this study, the number of hidden neurons varied
from two to 35, and the alternative transfer functions included
identity, logistic, tanh, exponential, gaussian and softmax. We applied the
enumerative combinatory method to exhaustively evaluate all
possible combinations of hidden neuron numbers and transfer
functions, then identified the combination with the best predictive
accuracy.
Cross-validation. Experiments have verified that the
predictive accuracy of an MLP initially increases with the
number of training iterations, but starts deteriorating after a
critical point, because the network becomes over-fitted to
recognize specific cases rather than learning general
Table 1. Baseline quantitative characteristics of the training set and validation set.
Variables Training set (N=290) Validation set (N=70) P-Value
Donor characteristics
D-Age (yr) 38.12612.33 37.88611.99 0.883
D-BMI 23.9565.84 24.8965.16 0.218
cold ischemia times (hour)* 8.6564.16 8.9264.03 0.624
warm ischemia times (min)* 9.6762.78 9.2662.65 0.265
Recipient characteristics
Age (yr) 45.25610.32 44.88610.18 0.787
BMI 20.0664.41 20.1864.35 0.838
HB (g/dl) 9.5865.36 9.0365.11 0.437
WBC (610
9) 6.3664.66 7.0564.69 0.268
PLT (610
9) 83.86685.58 79.99681.56 0.732
ALB (g/dl) 3.0660.65 2.8960.55 0.044
TB (mg/dl) 13.81614.66 12.39613.46 0.461
ALK (u/l) 161.466186.61 172.116185.32 0.668
GGT (u/l) 102.876184.35 97.566173.23 0.827
AST (u/l) 124.626176.05 149.766175.69 0.284
ALT (u/l) 113.066191.98 143.256183.21 0.234
BUN (mmol/l) 20.55616.86 21.02616.36 0.833
Crea (mg/dl) 1.1961.16 1.2661.15 0.650
APTT (s) 57.93625.69 62.57625.43 0.175
INR 2.1561.28 2.4961.26 0.046
Na
+ (mmol/l) 130.9769.65 129.5669.47 0.272
SOFA scores* 8.6961.76 8.7261.68 0.897
*Ischemia times and recipients’ SOFA scores were not used as candidate factors. BMI=body mass index; HB=hemoglobin; WBC=white blood cell; PLT=platelet;
BUN=blood urea nitrogen; Crea=creatinine; ALB=albumin; TB=total bilirubin; ALK=alkaline phosphatase; GGT=c-glutamyltransferase; AST=aspertate
aminotransferase; ALT=alanine aminotransferase; INR=international normalized ratio of prothrombin time; APTT=activated partial thromboplastin time; Na
+=serum
sodium; N/A=not applicable.
doi:10.1371/journal.pone.0031256.t001
Table 2. Sequential Organ Failure Assessment (SOFA) score.
Variables/score 0 1 2 3 4
PaO2/FiO2 (mmHg) .400 #400 #300 #200 #100
Platelets (610
3/uL) .150 #150 #100 #50 #20
Bilirubin (mg/dL) ,1.2 1.2–1.9 2–5.9 6–11.9 .12
Cardiovascular (Hg/kg/min)– MAP,70 Dop#5D o p .5
(Epi#0.1)
Epi.0.1
Glasgow Coma Scale 15 13–14 10–12 6–9 ,6
Creatinine (mg/dL) ,1.2 1.2–1.9 2–3.4 3.5–4.9 .5
MAP=mean arterial pressure; Dop=dopamine; Epi=epinephrine.
doi:10.1371/journal.pone.0031256.t002
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prevent this over-fitting is to use cross-validation to stop the
training at the point of maximum generalization.
Network training process. The training rule used in this
MLP was supervised, feedforward, back-propagation of error,
which could adjust the internal parameters of the network over
repeated training iterations to improve the overall accuracy, by
modifying the weight of the connections between neurons. In
detail, once an input variable is applied as a stimulus to the input
layer, it is propagated through hidden layer until an output is
generated; this output is then compared with the desired output
and an error signal is calculated; this error signal is then
transmitted backwards across the net and the weight of the
connections between neurons is updated to decrease the overall
error of the network; as training proceeds, the difference between
the network output and the desired output decreases to a
minimum [30].
Model Validation
The performances of the MLP, SOFA score, and MELD score
in predicting survival at posttransplant one year and two years
were assessed in a validation set by measuring both calibration and
discrimination ability [31]. We chose these two intervals because
outcome at posttransplant one year could reflect surgical and
perioperative risk [4], and outcome at two years could also capture
mortality associated with most transplant complications, such as
rejection and biliary stricture. Calibration refers to the degree of
correspondence between predicted and actual survival probabil-
ities. In this study, we used goodness-of-fit testing to evaluate
calibration by the Hosmer-Lemeshow test [32], in which the x
2
statistic is the sum of the squared differences between actual and
predicted survival probability. Discrimination is usually assessed
by the area under a receiver operating characteristic (ROC) curve
[33], which is equal to the index of concordance (i.e., c-statistic).
The ROC analysis was also performed to measure the sensitivity,
specificity, positive predictive value, negative predictive value, and
the total accuracy of these three predictive models.
Results
Outcomes of the entire series of recipients
Of the 360 DDLT recipients, the mean time on the waiting list
was 9.1663.56 months, and the median follow-up period was
56.23626.46 months. The overall 6-month, 1-, 2-, 3- and 5- year
survival rates were 89.6%, 86.1%, 82.9%, 78.2% and 73.1%,
respectively. Of the 360 recipients, 89 recipients (24.7%) died
during the 5-year follow-up period. Of these, 23 (6.4%) died within
the first 3 months after transplantation of various perioperative
causes, including severe fungal infection or sepsis (n=6), multiple
organ failure (n=4), hepatic artery thrombosis (n=3), acute
rejection (n=3), primary graft dysfunction (n=2), upper gastro-
intestinal bleeding (n=2), graft versus host disease (n=2), and
subarachnoid hemorrhage (n=1). 57 (15.8%) recipients died for
chronic graft dysfunction with different causes, such as the HBV or
HCV recurrence, biliary complications, pathologically-proven
chronic rejection, and hepatic vein stenosis, etc. The remaining
9 recipients (2.5%) died of other causes in long-term follow-up,
including severe fungus infection or sepsis (n=3), de novo cancers
(n=2), multi-organ failure (n=2), respiratory failure (n=1),
cerebral hemorrhage (n=1).
Recipients’ baseline characteristics
Table 1 and table S1 showed the baseline characteristics of the
modeling set and validation set. Most of the characteristics
between the two sets have no differences, but we also observed
significant differences in the percentage of HBV-DNA level, as
well as in the mean values of ALB and INR between the modeling
and validation set.
MLP input features selection
Two donor factors and ten recipient factors were identified as
optimal input features by the forwards stepwise selection
algorithm: donor age and BMI; serum concentration of HB,
Crea, ALB, TB, ALT, INR, Na
+; presence of pretransplant
diabetes; dialysis prior to transplantation, and microbiologically-
proven sepsis. As each sub-category of every categorical variable is
an input neuron, there are 18 input neurons in the MLP network.
Training and development of the MLP network
By enumerative combinatory method and making many
iterations of training and cross-validation in each combination,
we identified 12 hidden neurons that optimally delineated the
network and produced the best performance in both one- and two-
year intervals. The most appropriate transfer functions were
Logistic, Gaussian for one-year network, and Exponential, Identity for
two-year network (Fig. 1.).
Taking one input variable, HB as an example, Figure 2
represents the relationships between HB and other variables, and
the output prognosis of the trained MLP network. In every
subgraph, HB, another variable, and the output prognosis (ie., the
MLP target) composed a simulated 3-D rendering; the output
prognosis of the network is plotted versus HB and another
variable, and the curved surface represents the relationship
between HB, the other variable, and the output prognosis. In
such a simulated 3-D rendering composed of only two input
variables (HB and another variable) and the output prognosis,
there is a nonlinear relationship between HB, other variables, and
the output prognosis. The relationships between multi-variables
and the output prognosis would undoubtedly be even much more
complex in corresponding multidimensional space.
Model validation
With the Hosmer-Lemeshow test, a P-value greater than 0.05
and close to 1.0 is considered to indicate better calibration, and the
smaller the x
2 value, the better the calibration ability of a model
[34]. The MLP’s calibration ability (x
2=1.56, P=0.82 in one-year
prediction; x
2=1.74, P=0.78 in two-year prediction) was higher
than that of the SOFA and MELD in both intervals’ prediction
(Table 3).
Table 4 and Figure 3 show the discrimination of the MLP,
SOFA score, and MELD score for predicting posttransplant 1-
year and 2-year survival probability. The c-statistic values range
from 0 to 1, with 0.5 corresponding to what is expected by chance
alone and 1.0 to perfect discrimination. For a prognostic model, a
c-statistic below 0.7 generally suggests poor prediction, while a c-
statistic above 0.7 indicates a useful model, and a c-statistic greater
than 0.8 indicates excellent predictive accuracy [24]. The MLP
had c-statistics of 0.91 (P,0.001) and 0.88 (P,0.001) in one-year
and two-year prediction, respectively (Table 4 and Fig. 3). The c-
statistics of the SOFA were 0.70 (one-year) and 0.67 (two-year).
MELD yielded the least accurate predictions (Table 4 and Fig. 3).
Discussion
The large disparity between patient demand and donated
organs is a pressing problem for all transplant surgeons, especially
in the Asia-Pacific region. The best solution to this problem is still
in dispute, as there are two sometimes-contradictory principles of
A Predictive Model for Liver Transplants
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use [35]. Unfortunately, prioritizing extremely sick patients make
it likely that patients who are not as sick ‘‘will be forced to wait
until their condition worsens and their chances for success are also
diminished’’ [36], and patients who are very sick may have worse
posttransplant outcomes than healthier patients [37]. Thus, the
optimal system would offer grafts to those who are sufficiently sick
to justify the transplantation but not too sick to benefit from it
[38], that is, the urgency of need should be jointly optimized with
the likelihood of satisfactory outcomes so as to avoid ‘‘futile
transplantation’’.
Furthermore, OLT ranks among the most expensive medical
interventions [39], so the urgency-based principle has contributed
to rising healthcare costs [37,40]. An accurate prognostic model
could also help potential transplant recipients and their families
make informed decisions by providing them with information on
the patient’s posttransplant survival probability [11,13].
With the aforementioned goals, a newly-adopted lung allocation
score in the United States has incorporated likelihood of
posttransplant survival in addition to lung disease severity [41].
The liver transplantation field would also benefit from a
continuously optimized allocation system that prioritizes patients
who need grafts most, without sacrificing the overall utility of this
scarce resource. Such a system necessitates a strong prognostic
model that can identify potential recipients with satisfactory
survival prospects.
Over the past decade, MELD [42] has proved to be an excellent
marker of BESLD-specific illness severity and corresponding
pretransplant mortality risk, but many studies have also shown its
poor accuracy in predicting posttransplant survival [43,44], which
is consistent with our results. The SOFA score was originally
developed to quantitatively describe the degree of organ
dysfunction in six organ systems and to evaluate morbidity in
intensive care unit septic patients [26], but later studies found that
it could be applied equally well in non-septic critically ill patients
to measure individual or aggregate organ dysfunction and to
describe morbidity risk [45]. Since its introduction, the SOFA
score has also been widely applied to prognostic mortality
assessment in critically ill patients with good results [46], although
it was not developed for this purpose. In recent years, some
Figure 1. Topological architecture of the MLP network constructed in this study. The network consisted of 18 input neurons, 12 hidden
neurons, and 1 output neuron.
doi:10.1371/journal.pone.0031256.g001
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patients and have also proven its validity in mortality risk
assessment for BESLD patients [47–49]. We believe that because
BESLD patients usually display multiple-organ damage or
dysfunction, such as the renal failure, coagulopathy, and
encephalopathy, the SOFA is an excellent scoring model for
assessing BESLD patients’ illness severity and mortality risk.
Additionally, several studies have analyzed the predictive power of
SOFA on post-liver transplant mortality; although these achieved
some encouraging results in short-term prognosis assessment
[50,51], its value in long-term outcome prediction still requires
study. In this study, SOFA achieved good calibration abilities in
both intervals and satisfactory discrimination power in one-year
prediction, which is consistent with other studies [50,51], but its
accuracy was poor in two-year prediction. Although SOFA
encopasses the functions of multiple systems including respiratory,
hemostastics, hepatic, circulatory, and brain and kidney, it is not
specific enough to BESLD patients and is not tailored to
posttransplant outcome prediction. Lack of these specificities
may account for its discriminative and calibration inferiority to the
MLP network.
Although there have been many attempts to develop a specific
model to assess posttransplant prognosis, to date, they have not
achieved sufficient accuracy, or have simply categorized the
patients into various risk groups [4,11]; even with some of the most
comprehensive efforts, the predictive accuracy of these models has
always been reported in the 60–70% range [4,9,11–14] with no
single model being more accurate than any other. We believe
there are several possible explanations for this. First, the effect of
prognostic factors depends on the underlying liver disease [11–13].
Thus, effort would be better spent developing disease-specific
models targeted to BESLD patients or cancer patients. Second,
Existing studies rely heavily on a few specific variables derived
from linear regression analyses, rather than from data mining. The
omission of many variables may hinder the discovery of underlying
relationships between prognosis and related factors, and the
interactions among factors. Third, transplant recipients represent
a very complex biological system where the relationship between
Figure 2. Curved surface diagram of outcome prediction in the MLP network (taking HB as an example). (2A): The one-year network.
The x-axis represents input variable HB (x1), while the y-axis represents another variable: donor BMI (x2), TB (x3), or ALB (x4). The z-axis represents the
output prognosis (ie., the MLP target). (2B): The two-year network. The x-axis represents HB (x1), and the y-axis represents another variable: Crea (x5),
INR (x6), or Na
+ (x7). The z-axis represents the output prognosis.
doi:10.1371/journal.pone.0031256.g002
Table 3. Calibration for MLP, SOFA, and MELD in
posttransplant survival prediction.
Goodness-of-fit (x
2) P-Value
Postransplant one-year survival prediction
MLP 1.56 0.82
SOFA 5.26 0.26
MELD 6.48 0.17
Postransplant two-year survival prediction
MLP 1.74 0.78
SOFA 5.64 0.23
MELD 6.98 0.14
doi:10.1371/journal.pone.0031256.t003
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mensional and nonlinear (as shown in Fig. 2) [17,23], so linear
methods are inadequate in predicting regression coefficients and
constructing risk factor models.
With the development of artificial intelligence in recent years,
ANN has been a superior data-mining solution for complex
prognostic problems [17,20], and MLP has been proven to
perform better than other architectures such as radial basis
function, recurrent neural network, and self-organizing map [22].
MLP is a computation system that uses a large number of simple
units to process information in parallel, so it is capable of learning
arbitrarily complex nonlinear functions to arbitrary accuracy levels
[22]. Furthermore, MLP allows a certain degree of flexibility when
it comes to handling noise [18]. Most importantly, MLP is a
nonparametric dynamic model, which can automatically self-
training and readjust the internal parameters by back-propagation
when more transplants enter the network [52], thus yielding more
accurate responses and becoming progressively more dependable
over time; this is what the linear models could not achieve.
In this study, although three characteristics of the recipients in
the validation set differed from the training set, the MLP still
achieved good calibration ability and high discrimination power in
posttransplant survival prediction, with c-statistics around 0.9 and
satisfactory sensitivity and specificity in both intervals, as well as
the small x
2 statistics and associated P-values around 0.8 in both
intervals. These results were not only superior to that of the linear
regression models reported in previous studies [4,9,12,13], but also
outstripped the performances of SOFA and MELD in this study.
We believe that several factors may account for the MLP’s
outstanding performance. First, the MLP network, employing 12
variables to make predictions, included more comprehensive
information associated with the posttransplant prognosis. Second,
the input features of our MLP included not only donor factors and
measurements of disease severity, but also some well-recognized
variables reflecting the complications and comorbidities (such as
sepsis and diabetes) in BESLD patients. Meanwhile, it should be
noted that we decided not to include some subjective variables
(such as encephalopathy or ascites) in our model development
Figure 3. ROC curves for MLP, SOFA score, and MELD score in posttransplant survival prediction. (3A): Posttransplant one-year
prediction. (3B): Posttransplant two-year prediction.
doi:10.1371/journal.pone.0031256.g003
Table 4. Discrimination of MLP, SOFA, and MELD in posttransplant survival prediction.
C-statistic ± SE 95% CI Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) P-Value
Posttransplant one-year survival prediction
MLP 0.9160.05 0.80–0.97 91.3 88.6 84.0 93.9 89.7 ,0.001
SOFA 0.7060.08 0.54–0.86 72.0 66.7 62.1 75.9 69.0 0.04
MELD 0.6660.10 0.47–0.84 68.0 63.6 58.6 72.4 65.5 0.10
Posttransplant two-year survival prediction
MLP 0.8860.07 0.74–0.96 88.0 84.8 81.5 90.3 86.2 ,0.001
SOFA 0.6760.09 0.50–0.84 68.0 66.7 60.7 73.3 67.2 0.07
MELD 0.6560.10 0.47–0.84 64.0 63.6 57.1 70.0 63.8 0.11
PPV=positive predictive value; NPV=negative predictive value.
doi:10.1371/journal.pone.0031256.t004
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arbitrary. Third, being computer-based, the MLP can process
more information about the survival process and model much
more complex nonlinear multidimensional relationship, thus
yielding more accurate prognostic estimations.
In this study, donor age and BMI were identified as input
features. These two factors could be obtained before transplan-
tation, and have been proved to be associated with graft quality
[53,54] and recipient outcomes [9,14]. Although some other
donor factors (such as the graft steatosis and ischemia times) may
directly reflect graft quality and contribute to posttransplant
prognosis, they would have been difficult or impossible to know
when clinicians and patients make transplant acceptance decisions
and when candidates are ranked on a waiting list. This problem
would seem to be an inherent difficulty in pretransplant
prediction. Therefore, in order to maximize the practical
applicability of a pretransplant model, we believe that it must be
constructed in accordance with actual clinical conditions, and
enhancing the model’s performance based on the variables
available is the most important goal. Thus, we decided not to
include this kind of characteristics in our pretransplant model
development.
Meanwhile, we chose posttransplant one-year and two-year as
the study endpoints in this study because outcomes within this
timeframe could reflect surgical and perioperative risk [4] and
mortality associated with most early complications. However, as
we know, the recipient’s long-term survival would be affected by
not only the pretransplant characteristics, but also many
intraoperative and posttransplant factors, such as the graft cold-
ischemia time and biliary complications. Thus, in our view, once
the appropriate modeling method is identified, development of
sequential correction models according to the different variable
acquisition phases may be a reasonable way to meet the evaluation
requirement in different phases. When certain donor character-
istics, operative parameters, and even some posttransplant
variables could be available after operation, another posttransplant
predictive model that incorporated above features should be
developed and used to perform a further corrective assessment.
We believe the two kinds of model can provide more
comprehensive perioperative evaluation information at different
variable acquisition phases, and, most importantly, they are
consistent with actual clinical conditions.
In this study, we clarified the complex multidimensional and
nonlinear relationship between transplant variables and posttrans-
plant outcomes, and identified the value of MLP in solving this
complex prognostic problem. We believe this methodological
result is the key point of this study, and is more important than the
specific factors and specific study intervals included in the
presented model.
We believe that this kind of pretransplant model would provide
patients and clinicians with important reference information about
their early posttransplant prospects during the initial counseling
and evaluation phases of referral [4,11,13]. If used alongside the
MELD system, the pretransplant model can also help predict early
outcome with and without transplantation. This provides
clinicians with a combined tool to identify patients likely to
benefit most from transplantation [9].
Meanwhile, how to ethically balance medical urgency with
posttransplant survival prospects is an important issue. For
instance, it could be argued that the patient with the highest
combined MELD score and survival prospects should be given
priority. But we expect that in practice, scientifically combining
the two conflicting determinants would not be so simple, just as the
use of MELD to guide graft allocation has sparked a wealth of
studies and discussion. Therefore, we believe that comprehensively
considering and weighing urgency and survival prospects will
require further evidence-based research. Whatever shape the final
system takes, however, it will undoubtedly include a prognostic
model with high predictive accuracy as an important component.
Although this MLP model was more sophisticated than
conventional linear models, in practical application, its software
implementation allowed the creation of a new interface that can be
incorporated into a website and be easily used by everyone, as in
the UNOS website, where an interface was created for MELD
calculation. Thus, we believe the model’s complexity should not
present a problem in clinical practice.
Despite our encouraging results, our study has some potential
limitations. First, it was developed using data from a single center;
we did not validate our model externally with data from different
sources. Indeed, we divided our dataset into training and
validation sets, and the validation samples were not used in model
development. Thus, the proposed MLP network should be further
verified with data at other major centers. Fortunately, the dynamic
nature of the MLP makes it capable of continuously and
automatically adjusting its internal parameters and improving as
more transplant data from other centers enter the network [52].
Second, the patient population had a high proportion of HBV
infection; therefore, this MLP network may have limited
applicability to typical North American and European patients,
who tend to have a lower rates of HBV but higher rates of hepatitis
C and alcoholism than do Chinese BESLD patients.
In summary, artificial intelligence methodologies such as MLP
offer significant advantages over conventional statistical techniques
in variable selection and dealing with restrictive assumptions of
normality and linearity, and thus hold promise for solving
posttransplant outcome prediction. Therefore, in future research
we plan to use MLP to develop a posttransplant multi-interval
sequential correction model, a step toward establishing a balanced
system that considers both pretransplant mortality and expected
posttransplant survival.
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